Drugs & TargetsFree Rucaparib receives FDA approval for BRCA-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree Ripretinib receives FDA approval for advanced gastrointestinal stromal tumor May 22, 2020Vol.46 No.21
Drugs & TargetsFree Tecentriq receives FDA approval as first-line monotherapy in NSCLC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Olaparib receives FDA approval for HRR gene-mutated metastatic castration-resistant prostate cancer May 22, 2020Vol.46 No.21
Drugs & TargetsFree BRACAnalysis CDx receives approval as companion diagnostic for Lynparza in mCRPC indication May 22, 2020Vol.46 No.21
Drugs & TargetsFree Karyopharm submits sNDA for Xpovio as treatment for multiple myeloma after at least one prior line of therapy May 22, 2020Vol.46 No.21
Drugs & TargetsFree FDA approves Retevmo, first therapy for lung and thyroid cancers with RET gene alterations May 15, 2020Vol.46 No.20
Drugs & TargetsFree FDA approves Lynparza + bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers May 15, 2020Vol.46 No.20
Drugs & TargetsFree FDA approves Tabrecta, first targeted therapy to treat metastatic NSCLC May 08, 2020Vol.46 No.19
Drugs & TargetsFree FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma May 08, 2020Vol.46 No.19
